Speaker 1: Mattia Falcone (Trumpp Lab): BCAT1 restricts aKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation - Speaker 2: Richard Schlenk (Clinical Talk): Lessons learned from Gemtuzumab Ozogamicin and Midostaurin approvals and translation into new trial concepts